Alps Group Inc. announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program, following the publication of a preliminary retrospective clinical case series. The study, published in SAGE Open Medical Case Reports, evaluated nebulized human umbilical cord mesenchymal stem cell (hUCMSC) derived exosome therapy in patients with asthma and/or chronic obstructive pulmonary disease (COPD). The study reported preliminary clinical observations suggesting improvements in pulmonary function, stability in inflammatory markers, and the absence of significant adverse effects. Each treatment consisted of 1 ml of exosome solution mixed with 5 ml of saline, administered via inhalation once weekly for five weeks. The company emphasized that larger-scale, controlled studies are necessary to confirm these results and to establish standardized treatment protocols.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alps Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645956-en) on January 30, 2026, and is solely responsible for the information contained therein.